Video interview : the biomedical attraction of magnetic nanoparticles

In this video interview, Kevin O’Grady, professor of physics at the University of York and magnetic materials specialist, provides an overview of the fundamental science of magnetic nanoparticles and their potential for diagnostic and therapeutic applications.

[[[ Additional link suggested by Nanocolors :
# Magnetic nanoparticles : volumetry in patents since 2000 ]]]

Focus on nanotech companies in the biomedical sector

This post focuses on companies specifically developping/proposing nanotech-based products & applications in the biomedical sector ; for each company listed below the specific area of activity and/or a flagship product or application are also mentionned :
<> BIND Biosciences (USA) : therapeutic targeted nanoparticles
<> BioNanomatrix (USA) : nanochannel array technology for genome analysis
<> Calando Pharmaceuticals (USA) [...]

New phase I clinical trial : antibacterial properties of silicon incorporated with quaternary ammonium polyethylenimine nanoparticles

The Hadassah Medical Organization plan to start in January 2010 a phase I clinical trial entitled “Antibacterial properties of silicon incorporated with quaternary ammonium polyethylenimine nanoparticles” now registered in the Clinicaltrials.gov database under reference NCT01007240. According to this page, “the aim of this study is to evaluate the antibacterial activity of crosslinked quaternary ammonium polyethylenimine (PEI) nanoparticles [...]

Focus on medical/pharma-related nano trends

Medical and pharma applications of nanotech are one of the key editorial lines of Nanocolors blog ; here is a recap of the 10 medical/pharma-related trend charts already released, ranked by number of visits.
Nano patents & the top 10 big pharmaceutical companies
Nanoparticles in clinical trial phases
Nanoparticles in clinical trials since 2000
Nano & drug delivery [...]

New phase I clinical trial : BikDD nanoparticles in patients with advanced pancreatic cancer

The MD Anderson Cancer Center and the National Cancer Institute plan to start in May 2010 a phase I clinical trial involving a nanoparticle formulation, now registered in the Clinicaltrials.gov database under reference NCT00968604. According to this page, “the goal of this clinical research study is to find the highest tolerable dose of BikDD nanoparticle that [...]

Nanoparticles & cancer therapy : volumetry in biomedical publications since 2000

This chart was built by searching PubMed for publications mentionning nanoparticles and “cancer therapy” in their title or abstract.

Preclinical efficacy of calcium nanoparticles adjuvanted influenza vaccines including H1N1 and H5N1

According to a presentation entitled “BioVant Calcium Phosphate (CaP) Nanoparticles: An Effective Safe Adjuvant for Influenza Vaccines including H1N1 and H5N1” given by BioSante Pharmaceuticals at the Immunotherapeutics & Vaccine Summit (ImVacS) last week : ”BioSante’s vaccine adjuvant, BioVant™, increased the protective effect of vaccines for multiple flu strains, including a potential new vaccine against H1N1 [...]

NanoDDS’09

The 2009 Nanomedicine and Drug Delivery Symposium (NanoDDS’09), co-organized and co-sponsored by Lilly, will take place in Indianapolis (Indiana, USA) on October 5th and 6th. The program is available here. According to the website of the event : “(…) the 2009 edition of this meeting focuses on a program that highlights the latest groundbreaking discoveries [...]

Nano & the top 10 big pharmaceutical companies – a cautious involvement ?

Based on an estimation using the Espacenet database, this chart illustrates how the top 10 big pharmaceutical companies (according to 2008 IMS Health data) rank in terms of number of nano-related patents.
With a few additional comments  :  
- Most of these companies only applied for a small number of nanotech-related patents so far ; but [...]

Nano & vaccines : volumetry in patents since 2000

This chart was built by searching the Espacenet database for patents mentionning the prefixes “nano” and “vaccin” in their title or abstract.